# Phase II Study of Chlorambucil and Subcutaneous Rituximab in Patients With Extranodal MALT Lymphoma

> **NCT01808599** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **International Extranodal Lymphoma Study Group (IELSG)** · enrollment: 112 (actual)

## Conditions studied

- MALT Lymphoma

## Interventions

- **DRUG:** Chlorambucil
- **DRUG:** Rituximab i.v.
- **DRUG:** Rituximab s.c.

## Key facts

- **NCT ID:** NCT01808599
- **Lead sponsor:** International Extranodal Lymphoma Study Group (IELSG)
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2013-12
- **Primary completion:** 2016-03
- **Final completion:** 2028-09
- **Target enrollment:** 112 (ACTUAL)
- **Last updated:** 2026-01-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01808599

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01808599, "Phase II Study of Chlorambucil and Subcutaneous Rituximab in Patients With Extranodal MALT Lymphoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01808599. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*